Sentinel lymph node mapping in early‐stage breast cancer: Technical issues and results with vital blue dye mapping and radioguided surgery

Axillary lymph node status is the most important prognostic factor in patients with operable breast cancer. Recent studies have demonstrated the possibility of identifying the sentinel lymph node (sN) as a reliable predictor of axillary lymph node status in both cutaneous melanoma and breast cancer. Sentinel lymph node identification proved feasible by either peritumoral dye injection (Patent Blue‐V) or radiodetection, with identification rates of 65–97% and 92–98%, respectively. However, some important issues need further definition, namely (a) optimization of the technique for intraoperative detection of the sN, (b) predictive value of the sN with regard to axillary lymph node status, and (c) reliability of intraoperative histology of the sN. We reviewed our experience in sN detection in patients with stage I–II breast cancer to assess the feasibility and accuracy of lymphatic mapping, by vital blue dye or radioguided surgery, and sN histology as a predictor of axillary lymph node status.

[1]  K. Miller,et al.  Impact of axillary lymph node dissection on the therapy of breast cancer patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Umberto Veronesi,et al.  Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes , 1997, The Lancet.

[3]  A. Luini,et al.  Distribution of axillary node metastases by level of invasion. An analysis of 539 cases , 1987, Cancer.

[4]  H. Sather,et al.  Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. , 1991, The New England journal of medicine.

[5]  S. Singletary,et al.  Clinical decision-making in early breast cancer. , 1993, Annals of surgery.

[6]  A. Recht,et al.  Axillary lymph nodes and breast cancer. A review , 1995, Cancer.

[7]  Donald L. Morton,et al.  Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer , 1994, Annals of surgery.

[8]  M. Lesser,et al.  Discontinuous or “Skip” Metastases in Breast Carcinomae: Analysis of 1228 Axillary Dissections , 1983, Annals of surgery.

[9]  B Fisher,et al.  Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. , 1985, The New England journal of medicine.

[10]  Axillary lymph node dissection for t1a breast carcinoma. Is it indicated? , 1994 .

[11]  P. Bruzzi,et al.  Prognostic role of lymph-node level involvement in patients undergoing axillary dissection for breast cancer. , 1998, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[12]  U. Veronesi,et al.  Axillary dissection can be avoided in selected breast cancer patients: analysis of 401 cases. , 1996, Anticancer research.

[13]  F. Rosato,et al.  Patterns of Axillary Nodal Involvement in Breast Cancer Predictability of Level One Dissection , 1982, Annals of surgery.

[14]  R. Steele,et al.  The efficacy of lower axillary sampling in obtaining lymph node status in breast cancer: A controlled randomized trial , 1985, The British journal of surgery.

[15]  M. Silverstein,et al.  Axillary lymph node dissection for intraductal breast carcinoma‐is it indicated? , 1987, Cancer.

[16]  A. Giuliano.  Guest editorial: Sentinel lymphadenectomy in primary breast carcinoma: An alternative to routine axillary dissection , 1996, Journal of surgical oncology.

[17]  Y. Maehara,et al.  Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. , 1996, Surgery.

[18]  A. Ketcham,et al.  Total axillary lymphadenectomy in the management of breast cancer. , 1991, Archives of surgery.

[19]  I Taylor,et al.  Assessment of morbidity from complete axillary dissection. , 1992, British Journal of Cancer.

[20]  A. Luini,et al.  Extent of metastatic axillary involvement in 1446 cases of breast cancer. , 1990, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  M. Cremonesi,et al.  Optimization of Axillary Lymphoscintigraphy to Detect the Sentinel Node in Breast Cancer , 1997, Tumori.

[22]  J. Thompson,et al.  Mammary lymphoscintigraphy in breast cancer. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[24]  M. Ross,et al.  Surgical management of stage I and II melanoma patients: approach to the regional lymph node basin. , 1996, Seminars in surgical oncology.

[25]  A. Giuliano,et al.  Improved Axillary Staging of Breast Cancer with Sentinel Lymphadenectomy , 1995, Annals of surgery.

[26]  T. Yeatman,et al.  Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. , 1996, JAMA.

[27]  J. Greenson,et al.  Identification of occult micrometastases in pericolic lymph nodes of Dukes' B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long‐term survival , 1994, Cancer.

[28]  C. Croce,et al.  Detection of hematogenous micrometastasis in patients with prostate cancer. , 1992, Cancer research.